Abbvie Inc. (ABBV) is garnering attention for its value as a long-term growth and large-cap value stock, especially amidst a recession. The biopharmaceutical giant continues to deliver a strong dividend and is considered a top dividend monarch with considerable growth prospects. Guggenheim has given ABBV a 'Buy' rating, and it's on the radar as a solid bet among innovative healthcare stocks for the year 2025. Their strong revenue growth and strategic outlook in the Q4 2024 earnings call have also contributed to the positive sentiment. Abbvie's impressive portfolio enhancements and growth from immunology drugs, Skyrizi and Rinvoq, continue to drive its market performance. However, share prices have experienced some negative fluctuation. They are also navigating the challenges of acquisition expenses, impacting their 2025 profit forecast. Despite this, many still consider AbbVie as a fruitful investment for beginners and a great stock to buy and hold for 3 years due to its stability and growth. The company has been progressing in its scientific advances and collaborations to develop novel cancer treatments and obesity drugs. However, the failure of two schizophrenia drug studies caused shares to slide. The company's future direction includes strengthening its focus on Alzheimer's disease through the impending acquisition of Aliada Therapeutics.
Abbvie ABBV News Analytics from Mon, 28 Oct 2024 07:00:00 GMT to Sat, 19 Apr 2025 15:14:47 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
